TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5

被引:32
作者
Karges, B
Krause, G
Homoki, J
Debatin, KM
de Roux, N
Karges, W
机构
[1] Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany
[2] Inst Mol Pharmacol, D-13125 Berlin, Germany
[3] Hop Necker Enfants Malad, INSERM, U584, F-75006 Paris, France
[4] Univ Ulm, Dept Internal Med, Div Endocrinol, D-89081 Ulm, Germany
关键词
D O I
10.1677/joe.1.06208
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mutations of the human thyrotrophin receptor (TSH-R) are a cause of thyroid adenomas and hyperthyroidism. Here we study mechanisms of receptor activation in a genomic TSH-R variant V509A located in transmembrane helix (TMH) 3, which we identify in a family with congenital hyperthyroidism, multiple adenomas and follicular thyroid cancer. Using molecular modelling and dynamic simulation, we predicted the release of amino acid residue A593 (located opposite in domain TMH5) from a tight 'knob-and-hole' interaction with TMH3, physiologically constrained in the native receptor state by the bulky side chain of V509. To experimentally validate this concept, we generated mutant TSH-R expression constructs for functional in vitro studies. TSH-R mutant V509A showed a 2.8-fold increase in basal cAMP production, confirming constitutive TSH-R activation. The addition of a second site suppressor mutant A593V to TSH-R V509A resulted in the normalization of basal cAMP release, and the dose-responsiveness to TSH ligand was maintained. These data thus demonstrate that TSH-R V509A activation is caused by the release of TMH3 - TMH5 interhelical constraints, while the native TSH-R conformation is re-stabilized by the introduction of a spacious valine residue at position 593. In conclusion, we delineate a novel mechanism of constitutive TSH-R activation, leading to thyroid hyperfunction and neoplasia.
引用
收藏
页码:377 / 385
页数:9
相关论文
共 43 条
[21]   Contrasting effects of activating mutations of GαS and the thyrotropin receptor on proliferation and differentiation of thyroid follicular cells [J].
Ludgate, M ;
Gire, V ;
Crisp, M ;
Ajjan, R ;
Weetman, A ;
Ivan, M ;
Wynford-Thomas, D .
ONCOGENE, 1999, 18 (34) :4798-4807
[22]   Hyperfunctioning malignant thyroid nodule in an 11-year-old girl: Pathologic and molecular studies [J].
Mircescu, H ;
Parma, J ;
Huot, C ;
Deal, C ;
Oligny, LL ;
Vassart, G ;
Van Vliet, G .
JOURNAL OF PEDIATRICS, 2000, 137 (04) :585-587
[23]   A free carboxylate oxygen in the side chain of position 674 in transmembrane domain 7 is necessary for TSH receptor activation [J].
Neumann, S ;
Krause, G ;
Chey, S ;
Paschke, R .
MOLECULAR ENDOCRINOLOGY, 2001, 15 (08) :1294-1305
[24]   Variant amino acids in the extracellular loops of murine and human vaso pressin V2 receptors account for differences in cell surface expression and ligand affinity [J].
Oksche, A ;
Leder, G ;
Valet, S ;
Platzer, M ;
Hasse, K ;
Geist, S ;
Krause, G ;
Rosenthal, A ;
Rosenthal, W .
MOLECULAR ENDOCRINOLOGY, 2002, 16 (04) :799-813
[25]   Crystal structure of rhodopsin: A G protein-coupled receptor [J].
Palczewski, K ;
Kumasaka, T ;
Hori, T ;
Behnke, CA ;
Motoshima, H ;
Fox, BA ;
Le Trong, I ;
Teller, DC ;
Okada, T ;
Stenkamp, RE ;
Yamamoto, M ;
Miyano, M .
SCIENCE, 2000, 289 (5480) :739-745
[26]   SOMATIC MUTATIONS CAUSING CONSTITUTIVE ACTIVITY OF THE THYROTROPIN RECEPTOR ARE THE MAJOR CAUSE OF HYPERFUNCTIONING THYROID ADENOMAS - IDENTIFICATION OF ADDITIONAL MUTATIONS ACTIVATING BOTH THE CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE AND INOSITOL PHOSPHATE-CA2+ CASCADES [J].
PARMA, J ;
VANSANDE, J ;
SWILLENS, S ;
TONACCHERA, M ;
DUMONT, J ;
VASSART, G .
MOLECULAR ENDOCRINOLOGY, 1995, 9 (06) :725-733
[27]   SOMATIC MUTATIONS IN THE THYROTROPIN RECEPTOR GENE CAUSE HYPERFUNCTIONING THYROID ADENOMAS [J].
PARMA, J ;
DUPREZ, L ;
VANSANDE, J ;
COCHAUX, P ;
GERVY, C ;
MOCKEL, J ;
DUMONT, J ;
VASSART, G .
NATURE, 1993, 365 (6447) :649-651
[28]   Lessons from constitutively active mutants of G protein-coupled receptors [J].
Parnot, C ;
Miserey-Lenkei, S ;
Bardin, S ;
Corvol, P ;
Clauser, E .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2002, 13 (08) :336-343
[29]  
Prader A, 1989, Helv Paediatr Acta Suppl, V52, P1
[30]   A Val 677 activating mutation of the thyrotropin receptor in a Hurthle cell thyroid carcinoma associated with thyrotoxicosis [J].
Russo, D ;
Wong, MG ;
Costante, G ;
Chiefari, E ;
Treseler, PA ;
Arturi, F ;
Filetti, S ;
Clark, OH .
THYROID, 1999, 9 (01) :13-17